Michael Kelliher
Direttore/Membro del Consiglio presso CAPRICOR THERAPEUTICS, INC.
Patrimonio netto: 1 M $ in data 31/05/2024
Posizioni attive di Michael Kelliher
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| CAPRICOR THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 01/09/2023 | - |
| Independent Dir/Board Member | 01/09/2023 | - | |
| ARDELYX, INC. | Corporate Officer/Principal | 25/03/2024 | - |
Storia della carriera di Michael Kelliher
Precedenti posizioni note di Michael Kelliher
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Corporate Officer/Principal | 01/01/2014 | - |
Formazione di Michael Kelliher
| University College Cork | Undergraduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 3 |
| Irlanda | 3 |
Posizioni
| Corporate Officer/Principal | 2 |
| Director/Board Member | 1 |
| Independent Dir/Board Member | 1 |
Settori
| Health Technology | 4 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| CAPRICOR THERAPEUTICS, INC. | Health Technology |
| ARDELYX, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
- Borsa valori
- Insiders
- Michael Kelliher
- Esperienza
